Physician profile
Max L Gratrix
NPI 1275737710
$3,484.89
in general payments reported to CMS, 2019-2025
25 companies · $660 in 2025
The $660 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $253 · 2021: $97.57 · 2022: $489 · 2023: $737 · 2024: $653 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,955 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,955.24 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $731.96 | 2019-2025 | |
| Lilly USA, LLC | $418.49 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $329.02 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $314.36 | 2019-2025 | Libtayo, Dupixent |
| Janssen Biotech, INC. | $285.65 | 2020-2024 | Tremfya |
| Amgen INC. | $227.87 | 2019-2025 | Otezla, Otezla |
| Leo Pharma INC. | $199.93 | 2019-2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $162.41 | 2019-2025 | |
| Genentech USA, INC. | $159.04 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $133.10 | 2021-2025 | Ilumya |
| Ucb, INC. | $119.85 | 2019-2025 | Bimzelx |
| Pfizer INC. | $82.79 | 2019-2024 | |
| Incyte Corporation | $80.43 | 2022 | |
| Vyne Pharmaceuticals INC. | $44.08 | 2020 | |
| Arcutis Biotherapeutics, INC. | $29.45 | 2023-2024 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $26.26 | 2019 | |
| Mayne Pharma Commercial LLC | $22.61 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.24 | 2024 | Sotyktu |
| Galderma Laboratories, L.P. | $21.70 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $18.76 | 2023 | |
| Stemline Therapeutics INC. | $15.29 | 2019 | |
| Kyowa Kirin, INC. | $13.30 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $12.79 | 2021 | |
| Prugen, INC. Pharmaceuticals | $12.14 | 2019 | |
| Biofrontera INC. | $1.37 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Gratrix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.